Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group. Kramar A, et al. Among authors: bex a. Ann Oncol. 2015 Dec;26(12):2392-8. doi: 10.1093/annonc/mdv380. Epub 2015 Sep 14. Ann Oncol. 2015. PMID: 26371288 Free article. Review.
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.
Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G, Schmidinger M, Suárez C, de Velasco G; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Powles T, et al. Among authors: bex a. Ann Oncol. 2021 Dec;32(12):1511-1519. doi: 10.1016/j.annonc.2021.09.014. Epub 2021 Sep 28. Ann Oncol. 2021. PMID: 34597799 Free article. No abstract available.
Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy.
Johannsen M, Staehler M, Ohlmann CH, Flörcken A, Schmittel A, Otto T, Bex A, Hein P, Miller K, Weikert S, Grünwald V. Johannsen M, et al. Among authors: bex a. Ann Oncol. 2011 Mar;22(3):657-663. doi: 10.1093/annonc/mdq437. Epub 2010 Sep 24. Ann Oncol. 2011. PMID: 20870911 Free article.
Predictive factors of chronic kidney disease stage V after partial nephrectomy in a solitary kidney: a multi-institutional study.
Verhoest G, Patard JJ, Oger E, Rioux-Leclercq N, Peyronnet B, Bessède T, Laguna P, Barwari K, Rigaud J, Roupret M, Coffin G, Bernhard JC, Long JA, Zisman A, Berger J, Paparel P, Maurin C, Lechevallier E, Bertini R, Ouzaid I, Salomon L, Bex A, Farfara R, Ljungberg B, Rodriguez AR, Bensalah K. Verhoest G, et al. Among authors: bex a. Urol Oncol. 2014 Jan;32(1):28.e21-6. doi: 10.1016/j.urolonc.2012.10.003. Epub 2013 Feb 19. Urol Oncol. 2014. PMID: 23428536
368 results